Jag1 expression predicts therapeutic response in nash

Abstract

The present invention provides a method for treating a human subject afflicted with a metabolic disease with a pharmaceutical composition, comprising the steps of: (i) determining JAG1 expression level in the subject; (ii) identifying the subject as a predicted responder if JAG1 expression level is greater than 1.5 fg/ng 18S; and (iii) administering the pharmaceutical composition to the subject only if the subject is identified as a predicted responder.

1 . A method for treating a human subject afflicted with non-alcoholic fatty liver disease (NAFLD) with a pharmaceutical composition, wherein the pharmaceutical composition comprises an oligonucleotide that decreases JAG1 expression level. 
     
     
         2 - 42 . (canceled) 
     
     
         43 . The method of  claim 1 , wherein the oligonucleotide specifically targets hepatocytes. 
     
     
         44 . The method of  claim 43 , wherein the oligonucleotide is targeted to hepatocytes by employing N-acetyl galactosamine. 
     
     
         45 . The method of  claim 1 , wherein the oligonucleotide is an antisense oligonucleotide targeting JAG1. 
     
     
         46 . The method of  claim 1 , wherein the NAFLD is nonalcoholic steatohepatitis (NASH).